3月13日 - ** 以医疗保健为重点的空白支票公司Voyager Acquisition VACH.O股价盘前上涨8.8%至11.97美元
** 该公司称股东已批准其与瑞士生物技术公司 VERAXA Biotech AG 合并
** VERAXA开发基于抗体的药物，利用实验室制造的免疫蛋白来治疗疾病。
** VACH 称，几乎所有股东（99.67%）都在交易前赎回了股票以换取现金
** 公司称，赎回后信托账户将持有约 885,556 美元
** 合并后的公司预计将在纳斯达克交易所交易，股票代码为 VRXA，等待交易所批准
** 2025 年股价上涨约 6%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.